SEC Form 4 · accession 0000899243-16-029739
Coherus Oncology, Inc. · CHRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dennis M Lanfear
Officer — President and CEO · Director
Period of report
Sep 20, 2016
Accepted (ET)
Sep 22, 2016 · 4:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001512762
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par valueF2,F3 | Sep 20, 2016 | S | 4,010 | $31.7512 | D | 1,337,616 | I | By Trust |
| Common Stock, $0.0001 par valueF3 | Sep 21, 2016 | S | 50 | $31.75 | D | 1,337,566 | I | By Trust |
| Common Stock, $0.0001 par value | holding | — | — | — | 71,635 | D | ||
| Common Stock, $0.0001 par valueF4 | holding | — | — | — | 86,965 | I | By LLC |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
- F2The transaction was executed in multiple trades in prices ranging from $31.75 to $31.76, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- F3These shares are held by the Lanfear Revocable Trust, dated January 27, 2004, as restated, of which Reporting Person is a trustee.
- F4These shares are held by Lanfear Capital Advisors, LLC of which Reporting Person is President.